| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies | Company's Home Page |
| Genomica Corporation |
| 4001 Discovery Drive Suite 130, Boulder, CO 80303 * (303) 544-4000 |
| Business Description | The company is a leading provider of software products and services that enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. We believe our first product, Discovery Manager, offers the broadest set of software tools for genomics researchers of any commercially available product. |
| Offering Information Company has | |||
| Trading As | GNOM (NASNTL) | Industry | High-Tech (SIC 7371) |
| Type of Stock Offered | Common Shares | Filing Date | 3/15/00 |
| Domestic Shares Offered | 6,440,000 | Offer Date | 9/28/00 |
| Foreign Shares Offered | 0 | Filing Range | $16.00 - $18.00 |
| Company Shares | 6,440,000 | Offer Price | $19.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.330 |
| Gross Proceeds | $122,360,000 | Selling | $0.800 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 20,989,363 | Employees | 61 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CIBC World Markets | Lead Manager | (212) 667-7400 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 0.000 | 0.197 | 0.781 | - | - |
| Income from Oper. | - | - | -2.756 | -3.790 | -7.980 | - | - |
| Net Income | - | - | -2.738 | -3.755 | -7.579 | - | - |
| E.P.S | - | - | -2.800 | -3.810 | -7.130 | - | - |
| Revenue Growth (%) | - | - | - | 296.447 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.10 | - | - | ||||
| Cash Flow - Inv. | -3.09 | - | - | ||||
| Cash Flow - Fin. | 6.48 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 7.55 | Current Assets | 6.85 | Current Ratio | 4.27 |
| Total Liab. | 1.87 | Current Liab. | 1.60 | Debt Ratio | 24.80% |
| Total Equity | 5.68 | Working Cap. | 5.25 | Debt to Equity Ratio | 0.33 |
| Cash | 3.52 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to continue development of Discovery Manager and new products; expand our sales and marketing activities; acquire complementary technologies; products or companies; repay capital lease obligations; and for general corporate purposes |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | McDermott, Will & Emery |
| Registrar/Transfer Agent | American Securities Transfer and Trust |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Kaufmann Fund, Inc., The | 25.50 | |
| Falcon Technology Partners, L.P. | 19.30 | |
| INVESCO Global Health Sciences Fund | 16.60 | |
| ARCH Venture Fund III, L.P. | 11.00 | |
| Boulder Ventures Limited | 6.50 | |
| Note: represents ownership of 5% or more prior to the offering. | ||